DE60238856D1 - Anthranilsäureamide und ihre pharmazeutische verwendung - Google Patents

Anthranilsäureamide und ihre pharmazeutische verwendung

Info

Publication number
DE60238856D1
DE60238856D1 DE60238856T DE60238856T DE60238856D1 DE 60238856 D1 DE60238856 D1 DE 60238856D1 DE 60238856 T DE60238856 T DE 60238856T DE 60238856 T DE60238856 T DE 60238856T DE 60238856 D1 DE60238856 D1 DE 60238856D1
Authority
DE
Germany
Prior art keywords
acid amide
pharmaceutical use
anthranilic acid
anthranilic
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60238856T
Other languages
German (de)
English (en)
Inventor
Guido Bold
Pascal Furet
Paul William Manley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60238856D1 publication Critical patent/DE60238856D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
DE60238856T 2001-11-08 2002-11-07 Anthranilsäureamide und ihre pharmazeutische verwendung Expired - Lifetime DE60238856D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0126901.8A GB0126901D0 (en) 2001-11-08 2001-11-08 Organic compounds
GBGB0212917.9A GB0212917D0 (en) 2001-11-08 2002-06-05 Organic compounds
PCT/EP2002/012445 WO2003040101A1 (en) 2001-11-08 2002-11-07 Anthranilic acid amides and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
DE60238856D1 true DE60238856D1 (de) 2011-02-17

Family

ID=26246753

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60238856T Expired - Lifetime DE60238856D1 (de) 2001-11-08 2002-11-07 Anthranilsäureamide und ihre pharmazeutische verwendung

Country Status (25)

Country Link
US (1) US7067543B2 (enExample)
EP (2) EP2269988B1 (enExample)
JP (1) JP4179989B2 (enExample)
KR (1) KR100633814B1 (enExample)
CN (1) CN100467450C (enExample)
AR (1) AR037261A1 (enExample)
AT (1) ATE494278T1 (enExample)
AU (1) AU2002342889B2 (enExample)
BR (1) BR0213939A (enExample)
CA (1) CA2462390C (enExample)
DE (1) DE60238856D1 (enExample)
GB (2) GB0126901D0 (enExample)
HR (1) HRP20040412A2 (enExample)
IL (1) IL161163A0 (enExample)
MX (1) MXPA04004390A (enExample)
MY (1) MY136322A (enExample)
NO (1) NO326986B1 (enExample)
NZ (1) NZ532587A (enExample)
PE (1) PE20030540A1 (enExample)
PL (1) PL368417A1 (enExample)
PT (1) PT1446381E (enExample)
RS (1) RS29404A (enExample)
RU (1) RU2315756C2 (enExample)
TW (1) TWI260985B (enExample)
WO (1) WO2003040101A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
ES2619203T3 (es) 2004-01-28 2017-06-23 Mitsui Chemicals Agro, Inc. Derivados de amida, procesos para la producción de los mismos y método para su aplicación como insecticidas
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
WO2006070878A1 (ja) * 2004-12-28 2006-07-06 Astellas Pharma Inc. カルボン酸誘導体またはその塩
EP2145873A1 (fr) * 2008-06-17 2010-01-20 Commissariat A L'energie Atomique Nouveaux composés ayant une activité protectrice vis-à-vis de l'action de toxines et de virus au mode d'action intracellulaire
AR073216A1 (es) 2008-08-27 2010-10-20 Leo Pharma As Derivados de piridina como receptor de vegfr-2 e inhibidores de proteina tirosina quinasa y uso farmaceutico de los mismos
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226394A (en) * 1964-06-16 1965-12-28 Shulton Inc Pyridylethylated anthranilamides and derivatives thereof
CA2155662A1 (en) * 1993-12-27 1995-07-06 Fumihiro Ozaki Anthranilic acid derivative
GB9511694D0 (en) * 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
WO1998014449A1 (en) 1996-10-02 1998-04-09 Novartis Ag Fused pyrazole derivatives and processes for their preparation
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
US6140351A (en) * 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
RS29404A (sr) 2007-02-05
NO20042137L (no) 2004-05-25
EP2269988A2 (en) 2011-01-05
RU2315756C2 (ru) 2008-01-27
HRP20040412A2 (en) 2005-06-30
MY136322A (en) 2008-09-30
IL161163A0 (en) 2004-08-31
EP1446381A1 (en) 2004-08-18
TWI260985B (en) 2006-09-01
KR100633814B1 (ko) 2006-10-13
JP2005508382A (ja) 2005-03-31
PT1446381E (pt) 2011-01-31
KR20050044374A (ko) 2005-05-12
TW200300086A (en) 2003-05-16
AR037261A1 (es) 2004-11-03
GB0212917D0 (en) 2002-07-17
NO326986B1 (no) 2009-03-30
EP1446381B1 (en) 2011-01-05
CA2462390C (en) 2011-01-11
PE20030540A1 (es) 2003-08-05
CA2462390A1 (en) 2003-05-15
EP2269988B1 (en) 2012-05-23
US20040248947A1 (en) 2004-12-09
JP4179989B2 (ja) 2008-11-12
MXPA04004390A (es) 2005-05-16
RU2004117548A (ru) 2005-06-10
ATE494278T1 (de) 2011-01-15
US7067543B2 (en) 2006-06-27
EP2269988A3 (en) 2011-02-16
WO2003040101A1 (en) 2003-05-15
PL368417A1 (en) 2005-03-21
NZ532587A (en) 2006-02-24
CN100467450C (zh) 2009-03-11
GB0126901D0 (en) 2002-01-02
CN1578768A (zh) 2005-02-09
AU2002342889B2 (en) 2007-03-01
BR0213939A (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
EE200300529A (et) Antraniilhappe amiidid, nende kasutamine ja farmatseutiline preparaat
NO2023030I1 (no) Apixaban and pharmaceutical acceptable salts thereof
ATE370958T1 (de) Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
ATE551322T1 (de) 3-z-1-(4-(n-((4-methylpiperazin-1- yl)methylcarbonyl)-n-methylamino)anilino)1- phenylmethylen-6-methoxycarbonyl-2- indolinonmonoethansulfonat und dessen verwendung als pharmazeutische zusammensetzung
ATE381335T1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
DE60201859D1 (de) Pharmazeutische Verwendung von N-Carbamoylazol-Derivate
DE60226704D1 (de) Acylierte 6,7,8,9-tetrahydro-5h-benzocycloheptenyl-amine und deren pharmazeutische verwendung
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
DE60103974D1 (de) Gyrase-inhibitoren und ihre verwendung
ATE279438T1 (de) Entzündungshemmende verbindungen und ihre verwendung
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60230591D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60237580D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
HUP0302845A3 (en) 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical
DE50211213D1 (de) Anthranilsäureamide mit heteroarylsulfonyl-seitenkette und ihre verwendung als antiarrhythmische wirkstoffe
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
DE60209486D1 (de) Pyranoindazole und ihre verwendung in der glaukombehandlung
DE60230883D1 (de) Neue formulierungen und ihre verwendung
ATE419366T1 (de) Tyra-gene und ihre verwendung
DE50206094D1 (de) Substituierte isoindole und ihre verwendung
DE60230162D1 (de) Polymerisate und ihre verwendung
ATE494278T1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
DE50202730D1 (de) Substituierte isoindole und ihre verwendung
DE602004022169D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
EP1379228A4 (en) (Z) -STYRYLBENZYLSULPONES AND THEIR PHARMACEUTICAL APPLICATIONS

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN